LAVA Therapeutics NV (LVTX)
2.26
-0.14
(-5.83%)
USD |
NASDAQ |
May 31, 16:00
2.28
+0.02
(+0.88%)
After-Hours: 20:00
LAVA Therapeutics Revenue (Quarterly): 6.992M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.992M |
| December 31, 2023 | 0.353M |
| September 30, 2023 | 0.053M |
| June 30, 2023 | 5.139M |
| March 31, 2023 | 1.224M |
| December 31, 2022 | 2.64M |
| September 30, 2022 | 15.26M |
| June 30, 2022 | 0.468M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.022M |
| December 31, 2021 | 1.066M |
| September 30, 2021 | 2.095M |
| June 30, 2021 | 1.08M |
| March 31, 2021 | 1.00M |
| December 31, 2020 | 2.081M |
| September 30, 2020 | 0.9709M |
| June 30, 2020 | 0.6658M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.053M
Minimum
Sep 2023
15.26M
Maximum
Sep 2022
2.632M
Average
1.073M
Median
Revenue (Quarterly) Benchmarks
| uniQure NV | 8.485M |
| ProQR Therapeutics NV | 4.834M |
| Merus NV | 7.889M |
| argenx SE | 401.00M |
| Pharming Group | 55.59M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.553M |
| Total Expenses (Quarterly) | 8.944M |
| EPS Diluted (Quarterly) | -0.02 |
| Enterprise Value | -29.86M |
| Profit Margin (Quarterly) | -7.91% |
| Earnings Yield | -46.90% |
| Normalized Earnings Yield | -47.12 |